Agenus Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AGEN Nasdaq 2836 www.agenusbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Agenus Inc.

Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - Feb 9th, 2026 11:00 am
LGND: New Year Program Updates - Feb 3rd, 2026 2:45 am
Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch - Jan 28th, 2026 6:00 pm
Agenus (AGEN) Q2 2025 Earnings Call Transcript - Jan 27th, 2026 9:43 am
Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Jan 21st, 2026 5:30 am
Agenus to Host First 2026 Stakeholder Webcast - Jan 20th, 2026 4:24 pm
Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal - Jan 16th, 2026 3:08 am
Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - Jan 15th, 2026 6:30 am
Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - Jan 15th, 2026 5:01 am
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? - Jan 13th, 2026 10:00 am
France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - Jan 12th, 2026 5:30 am
Agenus (AGEN) Q3 2024 Earnings Call Transcript - Jan 5th, 2026 4:24 pm
Agenus (AGEN) Q4 2024 Earnings Call Transcript - Jan 5th, 2026 2:52 pm
Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC - Dec 23rd, 2025 6:05 am
Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight - Dec 1st, 2025 3:31 pm
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL - Nov 19th, 2025 2:01 pm
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC - Nov 18th, 2025 6:41 am
LGND: Target Up On Improved Growth Outlook - Nov 10th, 2025 8:05 am
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates - Nov 10th, 2025 6:40 am
Agenus: Q3 Earnings Snapshot - Nov 10th, 2025 5:37 am